Bipolar androgen therapy for treatment of metastatic castration‐resistant prostate cancer: A case series
BAT represents a promising treatment strategy for mCRPC. This case series underscores BAT's potential to induce significant clinical and biochemical responses, resensitize tumors to ARPIs, and improve patients' quality of life. Despite eventual progression in some cases, BAT offers a period of disease control. Further research is needed to optimize patient selection and understand the molecular determinants of BAT responsiveness.
Authors
- Daniel Herchenhorn (ORCID: https://orcid.org/0000-0001-5166-848X)
- Emmanuel S. Antonarakis (ORCID: https://orcid.org/0000-0003-0031-9655)
- Alexander H. Song
- Eric Ovruchesky
- Mark Christopher Markowski (ORCID: https://orcid.org/0000-0003-2780-5100)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Aaron M. Lee (ORCID: https://orcid.org/0000-0002-9470-8151)
- Elizabeth Pan (ORCID: https://orcid.org/0000-0001-7025-9104)
- Elizabeth Tran
- S. Marley
- S. Denmeade
- Kyra Yamamoto
Institutions
- University of Minnesota (US)
- University of California San Diego (US)
- D’Or Institute for Research and Education (BR)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- The Prostate
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1002/pros.24798
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68